Reliability and validity of the CogState battery Chinese language version in schizophrenia

Na Zhong, Haifeng Jiang, Jin Wu, Hong Chen, Shuxing Lin, Yan Zhao, Jiang Du, Xiancang Ma, Ce Chen, Chengge Gao, Kenji Hashimoto, Min Zhao, Na Zhong, Haifeng Jiang, Jin Wu, Hong Chen, Shuxing Lin, Yan Zhao, Jiang Du, Xiancang Ma, Ce Chen, Chengge Gao, Kenji Hashimoto, Min Zhao

Abstract

Background: Cognitive impairment in patients with schizophrenia is a core symptom of this disease. The computerized CogState Battery (CSB) has been used to detect seven of the most common cognitive domains in schizophrenia. The aim of this study was to examine the reliability and validity of the Chinese version of the CSB (CSB-C), in Chinese patients with schizophrenia.

Methodology/principal findings: Sixty Chinese patients with schizophrenia and 58 age, sex, and education matched healthy controls were enrolled. All subjects completed the CSB-C and the Repeated Battery for the Assessment of Neuropsychological Status (RBANS). To examine the test-retest reliability of CSB-C, we tested 33 healthy controls twice, at a one month interval. The Cronbach α value of CSB-C in patients was 0.81. The test-retest correlation coefficients of the Two Back Task, Gronton Maze Learning Task, Social Emotional Cognition Task, and Continuous Paired Association Learning Task were between 0.39 and 0.62 (p<0.01) in healthy controls. The composite scores and all subscores for the CSB-C in patients were significantly (p<0.01) lower than those of healthy controls. Furthermore, composite scores for patients on the RBANS were also significantly lower than those of healthy controls. Interestingly, there was a positive correlation (r = 0.544, p<0.001) between the composite scores on CSB-C and RBANS for patients. Additionally, in the attention and memory cognitive domains, corresponding subsets from the two batteries correlated significantly (p<0.05). Moreover, factor analysis showed a two-factor model, consisting of speed, memory and reasoning.

Conclusions/significance: The CSB-C shows good reliability and validity in measuring the broad cognitive domains of schizophrenia in affected Chinese patients. Therefore, the CSB-C can be used as a cognitive battery, to assess the therapeutic effects of potential cognitive-enhancing agents in this cohort.

Conflict of interest statement

Competing Interests: Kenji Hashimoto is a member of the Editorial Board of PLOS ONE. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The other authors have declared that no competing interests exist.

Figures

Figure 1. Magnitude of impairment relative to…
Figure 1. Magnitude of impairment relative to healthy controls in the CSB-C.
Abbreviation: ISLT International Shopping List Task, DET Detection Task, IDN Identification Task, OCL One Card Learning Task, ONB One Back Task, CPAL Continuous Paired Association Task, GML Groton Maze Learning Task. Numbers of the figure are Z-score. **p

Figure 2. Magnitude of impairment relative to…

Figure 2. Magnitude of impairment relative to healthy controls in the RBANS.

Numbers of the…

Figure 2. Magnitude of impairment relative to healthy controls in the RBANS.
Numbers of the figure are Z-score. **p

Figure 3. Inter-correlations between the CSB-C composite…

Figure 3. Inter-correlations between the CSB-C composite score and the RBANS composite score.

Controls: r…

Figure 3. Inter-correlations between the CSB-C composite score and the RBANS composite score.
Controls: r  = 0.53, p
Similar articles
References
    1. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, et al. (2011) Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125: 161–168. - PubMed
    1. Wang CH, Li Y, Yang J, Su LY, Geng YG, et al. (2013) A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia. Schizophr Res 144: 129–135. - PubMed
    1. Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, et al. (2003) The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry 53: 422–430. - PubMed
    1. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, et al. (2008) Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 165: 978–987. - PubMed
    1. Hyman SE, Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science 299: 350–351. - PubMed
Show all 57 references
Publication types
Related information
Grant support
This study was funded by Ministry of Science and Technology (2012BAI01B07), National Nature Science Foundation (81271468, 81130020) and Shanghai one hundred talent project in health division (XBR2011015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 2. Magnitude of impairment relative to…
Figure 2. Magnitude of impairment relative to healthy controls in the RBANS.
Numbers of the figure are Z-score. **p

Figure 3. Inter-correlations between the CSB-C composite…

Figure 3. Inter-correlations between the CSB-C composite score and the RBANS composite score.

Controls: r…

Figure 3. Inter-correlations between the CSB-C composite score and the RBANS composite score.
Controls: r  = 0.53, p
Similar articles
References
    1. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, et al. (2011) Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125: 161–168. - PubMed
    1. Wang CH, Li Y, Yang J, Su LY, Geng YG, et al. (2013) A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia. Schizophr Res 144: 129–135. - PubMed
    1. Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, et al. (2003) The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry 53: 422–430. - PubMed
    1. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, et al. (2008) Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 165: 978–987. - PubMed
    1. Hyman SE, Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science 299: 350–351. - PubMed
Show all 57 references
Publication types
Related information
Grant support
This study was funded by Ministry of Science and Technology (2012BAI01B07), National Nature Science Foundation (81271468, 81130020) and Shanghai one hundred talent project in health division (XBR2011015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 3. Inter-correlations between the CSB-C composite…
Figure 3. Inter-correlations between the CSB-C composite score and the RBANS composite score.
Controls: r  = 0.53, p

References

    1. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, et al. (2011) Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125: 161–168.
    1. Wang CH, Li Y, Yang J, Su LY, Geng YG, et al. (2013) A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia. Schizophr Res 144: 129–135.
    1. Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, et al. (2003) The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry 53: 422–430.
    1. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, et al. (2008) Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 165: 978–987.
    1. Hyman SE, Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science 299: 350–351.
    1. Kaneko Y, Keshavan M (2012) Cognitive remediation in schizophrenia. Clin Psychopharmacol Neurosci 10: 125–135.
    1. Dickinson D, Ramsey ME, Gold JM (2007) Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 64: 532–542.
    1. Gold JM, Goldberg RW, McNary SW, Dixon LB, Lehman AF (2002) Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 159: 1395–1402.
    1. Brekke JS, Long JD, Nesbitt N, Sobel E (1997) The impact of service characteristics on functional outcomes from community support programs for persons with schizophrenia: a growth curve analysis. J Consult Clin Psychol 65: 464–475.
    1. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, et al. (2012) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69: 562–571.
    1. Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, et al. (2010) Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry 167: 160–169.
    1. Sabbag R, Levin R, Edelman S, Heresco-Levy U (2011) Preventive pharmacological treatment --an evolving new concept in schizophrenia. Isr J Psychiatry Relat Sci 48: 82–90.
    1. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, et al. (2008) The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165: 203–213.
    1. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, et al. (2008) The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 165: 214–220.
    1. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, et al. (2011) The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 37: 1209–1217.
    1. Murthy NV, Mahncke H, Wexler BE, Maruff P, Inamdar A, et al. (2012) Computerized cognitive remediation training for schizophrenia: an open label, multi-site, multinational methodology study. Schizophr Res 139: 87–91.
    1. Maruff P, Thomas E, Cysique L, Brew B, Collie A, et al. (2009) Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 24: 165–178.
    1. Pietrzak RH, Snyder PJ, Jackson CE, Olver J, Norman T, et al. (2009) Stability of cognitive impairment in chronic schizophrenia over brief and intermediate re-test intervals. Hum Psychopharmacol 24: 113–121.
    1. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, et al. (2009) A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 31: 848–859.
    1. Randolph C, Tierney MC, Mohr E, Chase TN (1998) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20: 310–319.
    1. Zhang XY, Liu L, Liu S, Hong X, Chen da C, et al. (2012) Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry 169: 974–981.
    1. Wang JH, Li CB, Cheng Y, Yi ZH, Long B, et al. (2009) Reliability and validity of repeatable battery for the assessment of neuropsychological status (RBANS) in schizophrenic patients: a preliminary study. Shanghai Archives of Psychiatry 21: 265–268.
    1. Zhang XY, Chen da C, Xiu MH, Haile CN, Sun H, et al. (2012) Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study. PLoS One 7: e36563.
    1. Zhang XY, Chen da C, Xiu MH, Yang FD, Tan YL, et al. (2013) Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr Res 143: 301–306.
    1. First MB, Spitzer L, Gibbon M, Williams JBW (1995) Structured clinical interview for DSM-IV axis I disorders. New York NY: Biometrics Research Department.
    1. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.
    1. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, et al. (2004) The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68: 283–297.
    1. Wilk CM, Gold JM, Humber K, Dickerson F, Fenton WS, et al. (2004) Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res 70: 175–186.
    1. Azizian A, Yeghiyan M, Ishkhanyan B, Manukyan Y, Khandanyan L (2011) Clinical validity of the Repeatable Battery for the Assessment of Neuropsychological Status among patients with schizophrenia in the Republic of Armenia. Arch Clin Neuropsychol 26: 89–97.
    1. Zhang BH, Tan YL, Zhang WF, Wang ZR, Yang GG, et al. (2009) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a screening test in Chinese: reliability and validity. Chin Ment Heal J 28: 865–869.
    1. Bosc M, Dubini A, Polin V (1997) Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 7 Suppl 1: S57–70; discussion S71–53.
    1. Tse WS, Bond AJ (2007) Psychometric analysis of the Chinese version of Social Adaptation Self-evaluation Scale (C-SASS). Psychiatry Res 153: 277–281.
    1. Saxena S, Carlson D, Billington R (2001) The WHO quality of life assessment instrument (WHOQOL-Bref): the importance of its items for cross-cultural research. Qual Life Res 10: 711–721.
    1. Xia P, Li N, Hau KT, Liu C, Lu Y (2012) Quality of life of Chinese urban community residents: a psychometric study of the mainland Chinese version of the WHOQOL-BREF. BMC Med Res Methodol 12: 37.
    1. Cortina JM (1993) What is coefficient alpha? An examination of theory and applications.. Journal of Applied Psychology 78: 98–104.
    1. Falleti MG, Maruff P, Collie A, Darby DG (2006) Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol 28: 1095–1112.
    1. Hammers D, Spurgeon E, Ryan K, Persad C, Heidebrink J, et al.. (2011) Reliability of repeated cognitive assessment of dementia using a brief computerized battery. Am J Alzheimers Dis Other Demen 26..
    1. Collie A, Darekar A, Weissgerber G, Toh MK, Snyder PJ, et al. (2007) Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study. Contemp Clin Trials 28: 391–400.
    1. Keefe RS, Harvey PD (2012) Cognitive impairment in schizophrenia. Handb Exp Pharmacol: 11–37.
    1. Yoshida T, Suga M, Arima K, Muranaka Y, Tanaka T, et al. (2011) Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia. PLoS One 6: e20469.
    1. Rowland JE, Hamilton MK, Vella N, Lino BJ, Mitchell PB, et al... (2012) Adaptive Associations between Social Cognition and Emotion Regulation are Absent in Schizophrenia and Bipolar Disorder. Front Psychol 3 : doi: 10.3389/fpsyg.
    1. Allen DN, Strauss GP, Donohue B, van Kammen DP (2007) Factor analytic support for social cognition as a separable cognitive domain in schizophrenia. Schizophr Res 93: 325–333.
    1. Chung YS, Mathews JR, Barch DM (2011) The effect of context processing on different aspects of social cognition in schizophrenia. Schizophr Bull 37: 1048–1056.
    1. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64: 393–406.
    1. Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, et al. (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38: 968–975.
    1. Porter RJ, Gallagher P, Thompson JM, Young AH (2003) Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 182: 214–220.
    1. Hindmarch I, Hashimoto K (2010) Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol 25: 193–200.
    1. Hasselbalch BJ, Knorr U, Kessing LV (2011) Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord 134: 20–31.
    1. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, et al. (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7: e42676.
    1. Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ (2010) Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord 12: 364–375.
    1. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, et al. (2012) Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord 14: 478–487.
    1. Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, et al... (2013) Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand.
    1. Dean AC, Groman SM, Morales AM, London ED (2013) An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology 38: 259–274.
    1. Baldacchino A, Balfour DJ, Passetti F, Humphris G, Matthews K (2012) Neuropsychological consequences of chronic opioid use: a quantitative review and meta-analysis. Neurosci Biobehav Rev 36: 2056–2068.
    1. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59: 60–70.
    1. Zachariae R, Mehlsen MY (2011) Is chemotherapy associated with cognitive impairment? Nat Rev Urol 8: 182–183.
    1. Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T (2013) A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39: 297–304.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する